# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k072658   
B. Purpose for Submission: New Device   
C. Measurand: C-Reactive Protein (CRP)   
D. Type of Test: Latex-enhanced turbidimetric immunoassay, quantitative   
E. Applicant: Seimens Medical Solutions Diagnostics   
F. Proprietary and Established Names: ADVIA™ Chemistry C-Reactive Protein_2 (CRP_2) Assa ADVIA™ Chemistry C-Reactive Protein_2 Calibrators

# G. Regulatory Information:

1. Regulation section: 866.5270 C-reactive protein immunological test system 862.1150 Calibrator   
2. Classification: Class II   
3. Product code: DCN System, test, c - reactive protein JIX Calibrator, multi-analyte mixture   
4. Panel: Immunology Clinical Chemistry

# H. Intended Use:

1. Intended use(s): The ADVIA™ Chemistry C-Reactive Protein_2 assay is for in vitro diagnostic use in the quantitative determination of the concentration of C-Reactive Protein (CRP) in human serum and plasma (lithium heparin) on the ADVIA Chemistry systems. Such measurements are used in the evaluation of infection, tissue injury, inflammatory disorders, and associated diseases. Increases in CRP values are non-specific for many disease processes and should not be interpreted without a complete clinical evaluation.

The ADVIA Chemistry C-Reactive Protein_2 Calibrators are for in vitro diagnostic use in the calibration of ADVIA Chemistry systems for the C-Reactive Protein_2 (CRP-2) method.

2. Indication(s) for use: Same as above   
3. Special conditions for use statement(s): Prescription use

# I. Device Description:

The ADVIA™ Chemistry C-Reactive Protein_2 assay consists of two liquid, ready-touse components: Reagent 1 is a glycine buffer solution; Reagent 2 is a suspension of uniform polystyrene latex particles coated with rabbit anti-CRP antibody.

The ADVIA Chemistry C- Reactive Protein_2 Calibrators consist of six (6) levels of protein stabilized matrices containing varying concentrations of recombinant human CRO. The Calibrators have targeted expected values (lot specific) of 0, 5, 20, 40, 160 and $3 2 0 ~ \mathrm { m g / L }$ . The Calibrators (1 mL/vial) are liquid and ready to use. Storage is at $2 { - } 8 ^ { \mathrm { { \circ } } } \mathrm { C }$ .

# J. Substantial Equivalence Information:

1. Predicate device name(s): ADVIA Chemistry C-Reactive Protein_2 Wide Range Calibrators ADVIA Chemistry C-Reactive Protein (CRP)   
2. Predicate K number(s): k022682 k992662   
3. Comparison with predicate:

ADVIA Chemistry C-reactive Protein_2   

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For in vitro diagnostic use inthe quantitative determinationof C-reactive Protein.measurements are used in theevaluation of infection, tissueinjury, inflammatorydisorders, and associateddiseases. Increases in CRPvalues are non-specific formany disease processes andshould not be interpretedwithout a complete clinicalevaluation.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Expected Values</td><td colspan="1" rowspan="1">&lt; 10 mg/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent matrix</td><td colspan="1" rowspan="1">Two liquid, ready-to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Capture Antibody</td><td colspan="1" rowspan="1">Rabbit anti-CRP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Standardization</td><td colspan="1" rowspan="1">CRM-470</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">6-point</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Serum or plasma (lithiumheparin)</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Assay Principle</td><td colspan="1" rowspan="1">Latex turbidimetricimmunoassay</td><td colspan="1" rowspan="1">Polyethyleneglycol assistedturbidimetricimmunoassay</td></tr><tr><td colspan="1" rowspan="1">Read wavelength</td><td colspan="1" rowspan="1">571 nm</td><td colspan="1" rowspan="1">340/694 nm</td></tr><tr><td colspan="1" rowspan="1">Analytical range</td><td colspan="1" rowspan="1">4 to 336 mg/L</td><td colspan="1" rowspan="1">5-205 mg/L</td></tr><tr><td colspan="1" rowspan="1">On-board stability</td><td colspan="1" rowspan="1">60 days</td><td colspan="1" rowspan="1">30 days</td></tr></table>

ADVIA Chemistry C-Reactive Protein_2 Calibrators   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For in vitro diagnostic use inthe calibration of ADVIAChemistry systems for theCRP_2 method.</td><td rowspan=1 colspan=1>For in vitrodiagnostic use inthe calibration ofADVIAChemistrysystems for thewrCRP method.</td></tr><tr><td rowspan=1 colspan=1>Measurand</td><td rowspan=1 colspan=1>Recombinant human CRP</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>6 point calibration; 1 mL each</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Liquid, Ready-to-use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>CRM470</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Shelf life</td><td rowspan=1 colspan=1>18 months at 2-8°C</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>0, 5, 20, 40, 160, and 320mg/L; lot specific</td><td rowspan=1 colspan=1>0, 2.5, 10, 20, 80,and 160mg/L; lotspecific</td></tr><tr><td rowspan=1 colspan=1>Open-vialstability</td><td rowspan=1 colspan=1>60 days at 2-8°C</td><td rowspan=1 colspan=1>28 days at 2-8</td></tr></table>

# K. Standard/Guidance Document referenced (if applicable):

CLSI document EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline. CLSI EP17-A, Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline.

# L. Test Principle:

Sample is diluted by the instrument and then $4 0 ~ \mu \mathrm { L }$ of diluted sample is incubated with a buffer (Reagent 1). Reagent 2, a CRP_2 latex reagent, which is a suspension of uniform polystyrene latex particles coated with rabbit anti-CRP antibody, is added 10 minutes later. When serum or plasma containing CRP is mixed with the latex

reagent, agglutination takes place resulting in an increase in the turbidity. This turbidity is measured at $5 7 1 ~ \mathrm { { n m } }$ . The CRP concentration in serum or plasma is determined from a calibration curve that is generated with the CRP_2 calibrators.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Within-run and total precision were evaluated by testing three serum pools and 3 control levels on the ADVIA 1650. Samples were evaluated in duplicate in 2 runs per day for 10 days. Precision was evaluated using calculation methods in CLSI EP-5A2. Acceptance criteria (described below) were met.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Level mg/L</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.27</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 1*</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>221</td><td rowspan=1 colspan=1>2.48</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>3.24</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3*</td><td rowspan=1 colspan=1>310.7</td><td rowspan=1 colspan=1>22.86</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>22.86</td><td rowspan=1 colspan=1>7.4</td></tr></table>

$^ { * 5 }$ -day protocol

The acceptance criteria for precision performance are as follows:

<table><tr><td rowspan=2 colspan=1>C-RP concentration</td><td rowspan=1 colspan=2>AcceptanceCriteria</td></tr><tr><td rowspan=1 colspan=1>Within-runCV</td><td rowspan=1 colspan=1>Total CV</td></tr><tr><td rowspan=1 colspan=1>Lower range (~10mg/L)</td><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>8%</td></tr><tr><td rowspan=1 colspan=1>Upper range</td><td rowspan=1 colspan=1>≤ 10%</td><td rowspan=1 colspan=1>12%</td></tr></table>

Additionally, CRP_2 Control recoveries on each platform must be within $\pm$ $5 \%$ of the ADVIA 1650.

# b. Linearity/assay reportable range:

Linearity was evaluated by making equally spaced dilutions of a high serum pool with a low serum pool and comparing the expected vs. observed CRP concentration. Difference in recovery was $\leq 3 . 5 \%$ . Linear regression statistics demonstrated that the slope (and $9 5 \%$ CI) was 1.01 (0.987 to 1.034), y-intercept -0.10 (-4.35 to 4.14); $\mathrm { r } = 1 . 0$ .

<table><tr><td colspan="4" rowspan="1">ADVIA 1650 CRP_2 (mg/L)</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Expected</td><td colspan="1" rowspan="1">Observed</td><td colspan="1" rowspan="1">Recovery (%)</td></tr><tr><td colspan="1" rowspan="1">P1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">P2</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">100.6%</td></tr><tr><td colspan="1" rowspan="1">P3</td><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">98.7%</td></tr><tr><td colspan="1" rowspan="1">P4</td><td colspan="1" rowspan="1">114</td><td colspan="1" rowspan="1">115</td><td colspan="1" rowspan="1">100.5%</td></tr><tr><td colspan="4" rowspan="1">ADVIA 1650 CRP 2 (mg/L)</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Expected</td><td colspan="1" rowspan="1">Observed</td><td colspan="1" rowspan="1">Recovery (%)</td></tr><tr><td colspan="1" rowspan="1">P5</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">102.3%</td></tr><tr><td colspan="1" rowspan="1">P6</td><td colspan="1" rowspan="1">190</td><td colspan="1" rowspan="1">189</td><td colspan="1" rowspan="1">99.4%</td></tr><tr><td colspan="1" rowspan="1">P7</td><td colspan="1" rowspan="1">228</td><td colspan="1" rowspan="1">236</td><td colspan="1" rowspan="1">103.5%</td></tr><tr><td colspan="1" rowspan="1">P8</td><td colspan="1" rowspan="1">267</td><td colspan="1" rowspan="1">270</td><td colspan="1" rowspan="1">101.1%</td></tr><tr><td colspan="1" rowspan="1">P9</td><td colspan="1" rowspan="1">305</td><td colspan="1" rowspan="1">305</td><td colspan="1" rowspan="1">100.0%</td></tr></table>

The ADVIA Chemistry system has an ‘auto-dilution’ option to extend the measuring range above CRP concentrations of $3 0 4 ~ \mathrm { { m g / L } }$ (highest level calibrator). Samples above this are automatically diluted 3-fold by the system. The extended linearity of the ADVIA 1650 assay was evaluated by making equally spaced dilutions of two serum pools and comparing expected vs. observed CRP concentrations. Difference in recovery w $a s \leq 8 . 3 \%$ . Linear regression statistics for the entire assay range (0 to $1 0 7 1 \mathrm { m g / L }$ ) demonstrated that the slope (and $9 5 \%$ CI) was 1.033 (1.001 to 1.064), intercept was 2.04 (-12.85 to 16.94), $\mathrm { r } { = } 0 . 9 9 9$ .

<table><tr><td rowspan=1 colspan=4>ADVIA 1650 CRP_2 (mg/L)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Expected</td><td rowspan=1 colspan=1>Observed</td><td rowspan=1 colspan=1>Recovery (%)</td></tr><tr><td rowspan=1 colspan=1>P1</td><td rowspan=1 colspan=1>337</td><td rowspan=1 colspan=1>337</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>P2</td><td rowspan=1 colspan=1>521</td><td rowspan=1 colspan=1>542</td><td rowspan=1 colspan=1>104.1%</td></tr><tr><td rowspan=1 colspan=1>P3</td><td rowspan=1 colspan=1>704</td><td rowspan=1 colspan=1>763</td><td rowspan=1 colspan=1>108.3%</td></tr><tr><td rowspan=1 colspan=1>P4</td><td rowspan=1 colspan=1>888</td><td rowspan=1 colspan=1>942</td><td rowspan=1 colspan=1>106.2%</td></tr><tr><td rowspan=1 colspan=1>P5</td><td rowspan=1 colspan=1>1071</td><td rowspan=1 colspan=1>1071</td><td rowspan=1 colspan=1>100.0%</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Traceable to CRM-470.

Data and testing methodology were provided to support the open and closed stability claims in the labeling. Closed stability: 18 months at $2 { - } 8 ^ { \circ } \mathrm { C }$ ; Onboard stability 60 days. Calibrator stability 60 days $2 { - } 8 ^ { \mathrm { { \circ } } } \mathrm { C }$ .

d. Detection limit:

The Limit of detection (LoD) was obtained using the mean and SD of a blank and a low sample containing CRP $( { \sim } 3 \mathrm { m g / L } )$ ; and computed according to CLSI EP-17A protocol and determined to be $0 . 2 \mathrm { m g / L }$ , $\scriptstyle \mathrm { n = 4 0 }$ . The data support the low end claim for the analytical range as $4 \mathrm { m g / L }$ .

e. Analytical specificity:

Interference was evaluated by spiking human serum pools with hemoglobin (max $1 0 0 0 \mathrm { m g / d L }$ ), unconjugated and conjugated bilirubin (max $6 0 \mathrm { m g / d L } )$ ), Intralipid and avian triglycerides (max $1 0 0 0 \mathrm { m g / d L } )$ , and rheumatoid factor $\left( 2 0 0 \ : \mathrm { I U / m L } \right)$ . Multiple levels up to the maximum concentration listed of each of the interfering substances were tested at CRP concentration of ${ \sim } 5 \mathrm { m g / L }$ .

Interference was also tested on samples containing $1 0 \mathrm { m g / L }$ CRP using a single concentration of interferent (highest evaluated). All results passed the acceptance criteria for interference of $\leq 1 0 \%$ .

Prozone: No hook effect demonstrated up to $1 0 0 0 \mathrm { m g / L }$ of CRP.

Cross-reactivity: cross-reactivity to other substances was not evaluated. f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: The CRP_2 method on the ADVIA 1650 was compared to the ADVIA Chemistry CRP method on the same analyzer using the 35 samples that spanned the assay range. The mean of duplicate measurements were analyzed by Passing-Bablock regression analysis yielding the following results:

<table><tr><td rowspan=1 colspan=1>ComparisonMethod (x)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope(95% C.I.)</td><td rowspan=1 colspan=1>Intercept(95% C.I.)</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>SampleRange</td></tr><tr><td rowspan=1 colspan=1>ADVIAChemistry CRP</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0.970(0.938 to 1.00)</td><td rowspan=1 colspan=1>0.71(-1.48 to 2.56)</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>6.5 to 192.3mg/L</td></tr></table>

b. Matrix comparison:

A matrix comparison study was performed using matched serum and lithiumheparin plasma samples spanning the range of the assay. The results demonstrated equivalence between the matrices. Least square regression demonstrated the results:

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope(95% C.I.)</td><td rowspan=1 colspan=1>Intercept(95% C.I.)</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>SampleRange</td></tr><tr><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>0.999(0.987 - 1.011)</td><td rowspan=1 colspan=1>-0.01(-1.61 - 1.60)</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>6- 246 mg/L</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not available.   
b. Clinical specificity: Not available.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not available.

5. Expected values/Reference range: ${ < } 1 0 \ \mathrm { m g / L }$ (according to Tietz Clinical Guide to Laboratory Tests, $4 ^ { \mathrm { t h } }$ edition)

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision.